Intraventricular injection of STZ has been demonstrated to induce insulin resistance in the brain and significantly reduce the insulin receptor IRS-2, accompanied by significant memory loss, Aβ deposition and tau phosphorylation. This evidence concerns the gene MAPT and Insulin resistance.